Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity?

By sjmartinez • February 19, 2025

Sedrak MS, Asnani A. Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity? JACC CardioOncol. 2025 Feb;7(2):122-124. doi: 10.1016/j.jaccao.2025.01.004. PMID: 39967197.

Tags: breast cancer, Electronic health records, Geriatric oncology, Hematology/Oncology, Outcomes, Publications, Risk factor, Treatment, women’s oncology

Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study

LeVee A, Jacob S, Fisch S, Face C, Chengappa M, Chaudhry S, Baclig N, Soliman A, Ruel N, Wong M, Tsai K, Kang I, Kordic[...]

Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease

Kishan AU, Zekster Y, Singer AE, Taparra K, Valle LF, Steinberg ML, Nickols NG, Reiter RE, Czernin J, Calais J, Lee JK, Hardesty LR, Rettig[...]

Divergent evolution in bilateral prostate cancer: a case study

Haas R, Huang RR, Weiner AB, Patel Y, Liu LY, Yamaguchi TN, Agrawal R, Boutros PC, Reiter RE. Divergent evolution in bilateral prostate cancer: a[...]